8-K: Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

Instil Bio announces clinical progress of IMM2510/SYN-2510 in China by its collaborator, ImmuneOnco, including the dosing of the first patient in a Phase 1b/2 clinical trial and plans for a potential first-line NSCLC clinical trial in the second half of 2025.

Summary

• Instil Bio has announced clinical progress for IMM2510/SYN-2510 in China through its collaboration with ImmuneOnco.
• The first patient has been dosed in ImmuneOnco's Phase 1b/2 clinical trial of IMM2510/SYN-2510 combined with chemotherapy for advanced non-small cell lung cancer (NSCLC) in China.
• ImmuneOnco plans to enroll first-line patients in this trial and expects to present initial clinical data, including data for first-line NSCLC patients, in the second half of 2025.
• Instil Bio is targeting the initiation of a potential first-line advanced NSCLC clinical trial of IMM2510/SYN-2510 combined with chemotherapy in the second half of 2025, pending regulatory approvals.
• Instil believes that ImmuneOnco's initial clinical data in front-line NSCLC could be valuable in advancing the development of IMM2510/SYN-2510 in NSCLC and potentially lead to a global registrational study.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the clinical progress and planned trials, but tempered by the inherent risks and uncertainties in drug development and regulatory approvals.

Positives

• Clinical trials are progressing with the dosing of the first patient in the Phase 1b/2 trial in China.
• Initial clinical data from the trial in China is expected in the second half of 2025.
• Instil Bio is planning to initiate a clinical trial in the U.S. in the second half of 2025.
• The potential for a global registrational study in front-line NSCLC exists if the data is positive.

Risks

• The initiation of Instil's clinical trial is subject to necessary regulatory approvals.
• The development of SYN-2510/IMM2510 is subject to the risks and uncertainties associated with in-licensing product candidates and clinical trial collaborations.
• Clinical trials may not be successful, and results obtained to date may not be indicative of future results.
• Macroeconomic conditions, including international conflicts and U.S.-China trade tensions, could adversely affect Instil's business and operations.
• The regulatory approval process is time-consuming and uncertain.
• Competing product candidates may impact Instil's development programs.
• The company's cash resources may not be sufficient.

Future Outlook

Instil Bio is targeting the initiation of a potential first-line advanced NSCLC clinical trial of IMM2510/SYN-2510 combined with chemotherapy in the second half of 2025, assuming necessary regulatory approvals. ImmuneOnco's initial clinical data of IMM2510/SYN-2510 in combination with chemotherapy in patients with front-line NSCLC could be extremely valuable in advancing Instil's development of IMM2510/SYN-2510 in NSCLC, potentially leading to a global registrational study in front-line NSCLC.

Management Comments

• Bronson Crouch, CEO of Instil, stated that ImmuneOnco's initial clinical data of IMM2510/SYN-2510 in combination with chemotherapy in patients with front-line NSCLC could be extremely valuable in advancing Instil's development of IMM2510/SYN-2510 in NSCLC.
• Bronson Crouch believes that positive data could position Instil to open a potential global registrational study in front-line NSCLC.

Industry Context

The development of bispecific antibodies like SYN-2510/IMM2510 targeting PD-L1 and VEGF is part of a broader trend in immuno-oncology to enhance anti-tumor activity and overcome resistance mechanisms. Several companies are developing similar bispecific antibodies for solid tumors, including lung cancer. Success in this area could provide a significant advancement in NSCLC treatment.

Comparison to Industry Standards

• SYN-2510/IMM-2510 is differentiated from other PD-(L)1xVEGF bispecific antibodies by its VEGF trap, which binds multiple VEGF receptor ligands beyond VEGF-A.
• The bispecific structure leverages PD-L1 as an anchor in the tumor microenvironment (TME).
• SYN-2510/IMM-2510 has enhanced antibody-dependent cellular cytotoxicity (ADCC) to direct killing of PD-L1-positive tumor cells.

Stakeholder Impact

• Shareholders may react positively to the clinical progress and planned trials.
• Patients with NSCLC may benefit from the development of new treatment options.
• Employees of Instil Bio and ImmuneOnco are involved in the development and clinical trials.
• The collaboration between Instil Bio and ImmuneOnco impacts both companies' strategies and resources.

Next Steps

• ImmuneOnco will continue its Phase 1b/2 clinical trial of IMM2510/SYN-2510 in China.
• ImmuneOnco plans to present initial clinical data from its trial in the second half of 2025.
• Instil Bio plans to initiate a potential first-line advanced NSCLC clinical trial of IMM2510/SYN-2510 in the second half of 2025, subject to regulatory approvals.

Key Dates